Propella develops innovative, best-in-class therapeutics with an eye towards accelerated approval with mitigated risk. We use proven science to produce products that are smarter, safer and more effective.
We are a privately held development-stage company dedicated to bringing to market improved versions of previously approved drugs. Our lead product candidate, topical CGS-200-5, is being developed for the management of osteoarthritis (OA) and has successfully completed a Phase 2 study for pain due to knee OA. PRL-02 is currently in Investigational New Drug (IND)-enabling studies for prostate cancer and will begin clinical development in 2021. An earlier-stage program showing promise is PRL-01, in late-stage preclinical development for herpes virus infections.
All Propella product candidates are covered by granted patents or filed patent applications that are wholly owned by Propella.